Qualitative and quantitative demonstration of bead-to-bead transfer with bone marrow-derived human mesenchymal stem cells on microcarriers: utilising the phenomenon to improve culture performance

Research output: Contribution to journalArticlepeer-review


  • Qasim A. Rafiq
  • Steven Ruck
  • Mariana P. Hanga
  • Thomas R. J. Heathman
  • Karen Coopman
  • David J. Williams
  • Christopher J. Hewitt

Colleges, School and Institutes

External organisations

  • University College London Hospitals NHS Foundation Trust
  • Aston University
  • Loughborough University
  • PCT, a Hitachi Group Company


Human mesenchymal stem cells (hMSCs) are a key candidate for advanced cell therapies with numerous clinical trials investigating their potential to treat acute and chronic indications. However, important translational and manufacturing challenges need to be addressed to improve our capability for scalable production of fully functional cells. In this study, we have demonstrated, both qualitatively and quantitatively, the ability of bone marrow-derived hMSCs to migrate from one microcarrier to another, and, to populate fresh microcarriers when added into suspension culture. Additionally, we have shown that compared to inoculating a culture with cells in free suspension, inoculating 10% of near-confluent microcarriers from an initial seed microcarrier culture resulted in an increase in the cell growth rate and overall cell yield and a significant reduction in the lag phase. These findings were consistent across cells from three different BM-hMSC donors and across different culture medium conditions, foetal bovine serum-supplemented medium, human platelet lysate-supplemented medium and serum-free medium. This new cells-on-beads inoculation method is an effective means of process intensification with the potential to decrease manufacturing times and potentially costs of hMSC-based therapies.


Original languageEnglish
JournalBiochemical Engineering Journal
Early online date15 Nov 2017
Publication statusE-pub ahead of print - 15 Nov 2017


  • human mesenchymal stem cells , cell therapy bioprocessing, microcarriers, bioreactor, regenerative medicine, bead to bead transfer , process intensification

Sustainable Development Goals